| Literature DB >> 33618979 |
Lucia Gutierrez-Chamorro1, Eudald Felip2, Ifeanyi Jude Ezeonwumelu1, Mireia Margelí3, Ester Ballana4.
Abstract
Besides its prominent role in cell proliferation, cyclin-dependent kinases (CDKs) are key players in viral infections as both DNA and RNA viruses modify CDK function to favor viral replication. Recently, a number of specific pharmacological CDK inhibitors have been developed and approved for cancer treatment. The repurposing of these specific CDK inhibitors for the treatment of viral infections may represent a novel effective therapeutic strategy to combat old and emergent viruses. In this review, we describe the role, mechanisms of action, and potential of CDKs as antiviral drug targets. We also discuss the current clinical state of novel specific CDK inhibitors, focusing on their putative use as antivirals, especially against new emerging viruses.Entities:
Keywords: CDK; HIV; SARS-CoV-2; drug repurposing; viral infections
Year: 2021 PMID: 33618979 DOI: 10.1016/j.tim.2021.01.014
Source DB: PubMed Journal: Trends Microbiol ISSN: 0966-842X Impact factor: 17.079